TEVA
Teva Pharmaceutical Industries Limited
Drug Manufacturers - Specialty & Generic
Market Cap$41.93B
5Y Perf.+187.4%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
TEVA vs SUPN
Revenue, margins, valuation, and 5-year total return — side by side.
SUPN
Supernus Pharmaceuticals, Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$3.01B
5Y Perf.+116.7%
TEVA vs SUPN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | TEVA | SUPN |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
| Market Cap | $41.93B | $3.01B |
| Revenue (TTM) | $17.35B | $777M |
| Net Income (TTM) | $1.56B | $-29M |
| Gross Margin | 52.1% | 89.4% |
| Operating Margin | 13.2% | -5.5% |
| Forward P/E | 14.5x | 24.1x |
| Total Debt | $17.38B | $41M |
| Cash & Equiv. | $3.56B | $128M |
TEVA vs SUPN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
TEVA
SUPN
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Teva Pharmaceutical… (TEVA) | 100 | 287.4 | +187.4% |
| Supernus Pharmaceut… (SUPN) | 100 | 216.7 | +116.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TEVA vs SUPN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TEVA leads in 4 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Supernus Pharmaceuticals, Inc. is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
TEVA
Teva Pharmaceutical Industries Limited
The Growth Play
TEVA carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 4.3%, EPS growth 182.8%, 3Y rev CAGR 5.0%
- Lower P/E (14.5x vs 24.1x)
- 9.0% margin vs SUPN's -3.7%
Best for: growth exposure
SUPN
Supernus Pharmaceuticals, Inc.
The Income Pick
SUPN is the clearest fit if your priority is income & stability and long-term compounding.
- beta 0.78
- 228.4% 10Y total return vs TEVA's -28.3%
- Lower volatility, beta 0.78, Low D/E 3.9%, current ratio 1.90x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | SUPN | 8.6% revenue growth vs TEVA's 4.3% |
| Value | TEVA | Lower P/E (14.5x vs 24.1x) |
| Quality / Margins | TEVA | 9.0% margin vs SUPN's -3.7% |
| Stability / Safety | SUPN | Beta 0.78 vs TEVA's 1.13, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | TEVA | +104.6% vs SUPN's +69.0% |
| Efficiency (ROA) | TEVA | 3.9% ROA vs SUPN's -2.0%, ROIC 7.7% vs -2.8% |
TEVA vs SUPN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
TEVA vs SUPN — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLTEVALAGGINGSUPN
SUPNSupernus Pharmaceutic…
1leads
TEVATeva Pharmaceutical I…
3leads
6 Total Categories
CATEGORYLEADERvs SUPNMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
SUPN4/6
Valuation MetricsMultiples, price ratios, and targets
TEVA4/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
TEVA5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
TEVA5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
SUPN leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TEVA is the larger business by revenue, generating $17.3B annually — 22.3x SUPN's $777M. TEVA is the more profitable business, keeping 9.0% of every revenue dollar as net income compared to SUPN's -3.7%. On growth, SUPN holds the edge at +38.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | TEVATeva Pharmaceutic… | SUPNSupernus Pharmace… |
|---|---|---|
| RevenueTrailing 12 months | $17.3B | $777M |
| EBITDAEarnings before interest/tax | $3.3B | $29M |
| Net IncomeAfter-tax profit | $1.6B | -$29M |
| Free Cash FlowCash after capex | $1.2B | $82M |
| Gross MarginGross profit ÷ Revenue | +52.1% | +89.4% |
| Operating MarginEBIT ÷ Revenue | +13.2% | -5.5% |
| Net MarginNet income ÷ Revenue | +9.0% | -3.7% |
| FCF MarginFCF ÷ Revenue | +6.8% | +10.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.3% | +38.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +72.2% | +81.0% |
SUPN leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
TEVA leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, TEVA's 17.6x EV/EBITDA is more attractive than SUPN's 53.4x.
| Metric | TEVATeva Pharmaceutic… | SUPNSupernus Pharmace… |
|---|---|---|
| Market CapShares × price | $41.9B | $3.0B |
| Enterprise ValueMkt cap + debt − cash | $55.8B | $2.9B |
| Trailing P/EPrice ÷ TTM EPS | 30.01x | -76.88x |
| Forward P/EPrice ÷ next-FY EPS est. | 14.55x | 24.12x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 17.65x | 53.44x |
| Price / SalesMarket cap ÷ Revenue | 2.43x | 4.19x |
| Price / BookPrice ÷ Book value/share | 5.34x | 2.78x |
| Price / FCFMarket cap ÷ FCF | 36.52x | 65.45x |
TEVA leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
TEVA leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
TEVA delivers a 20.7% return on equity — every $100 of shareholder capital generates $21 in annual profit, vs $-3 for SUPN. SUPN carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to TEVA's 2.20x. On the Piotroski fundamental quality scale (0–9), TEVA scores 8/9 vs SUPN's 4/9, reflecting strong financial health.
| Metric | TEVATeva Pharmaceutic… | SUPNSupernus Pharmace… |
|---|---|---|
| ROE (TTM)Return on equity | +20.7% | -2.7% |
| ROA (TTM)Return on assets | +3.9% | -2.0% |
| ROICReturn on invested capital | +7.7% | -2.8% |
| ROCEReturn on capital employed | +8.0% | -3.4% |
| Piotroski ScoreFundamental quality 0–9 | 8 | 4 |
| Debt / EquityFinancial leverage | 2.20x | 0.04x |
| Net DebtTotal debt minus cash | $13.8B | -$87M |
| Cash & Equiv.Liquid assets | $3.6B | $128M |
| Total DebtShort + long-term debt | $17.4B | $41M |
| Interest CoverageEBIT ÷ Interest expense | 2.51x | — |
TEVA leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
TEVA leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TEVA five years ago would be worth $34,625 today (with dividends reinvested), compared to $17,801 for SUPN. Over the past 12 months, TEVA leads with a +104.6% total return vs SUPN's +69.0%. The 3-year compound annual growth rate (CAGR) favors TEVA at 58.4% vs SUPN's 12.4% — a key indicator of consistent wealth creation.
| Metric | TEVATeva Pharmaceutic… | SUPNSupernus Pharmace… |
|---|---|---|
| YTD ReturnYear-to-date | +16.3% | +5.7% |
| 1-Year ReturnPast 12 months | +104.6% | +69.0% |
| 3-Year ReturnCumulative with dividends | +297.5% | +42.1% |
| 5-Year ReturnCumulative with dividends | +246.2% | +78.0% |
| 10-Year ReturnCumulative with dividends | -28.3% | +228.4% |
| CAGR (3Y)Annualised 3-year return | +58.4% | +12.4% |
TEVA leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — TEVA and SUPN each lead in 1 of 2 comparable metrics.
Risk & Volatility
SUPN is the less volatile stock with a 0.78 beta — it tends to amplify market swings less than TEVA's 1.13 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TEVA currently trades 96.4% from its 52-week high vs SUPN's 87.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | TEVATeva Pharmaceutic… | SUPNSupernus Pharmace… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.13x | 0.78x |
| 52-Week HighHighest price in past year | $37.35 | $59.68 |
| 52-Week LowLowest price in past year | $14.99 | $29.16 |
| % of 52W HighCurrent price vs 52-week peak | +96.4% | +87.6% |
| RSI (14)Momentum oscillator 0–100 | 73.5 | 57.9 |
| Avg Volume (50D)Average daily shares traded | 6.6M | 604K |
Evenly matched — TEVA and SUPN each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates TEVA as "Buy" and SUPN as "Buy". Consensus price targets imply 14.8% upside for SUPN (target: $60) vs 8.3% for TEVA (target: $39).
| Metric | TEVATeva Pharmaceutic… | SUPNSupernus Pharmace… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $39.00 | $60.00 |
| # AnalystsCovering analysts | 46 | 14 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
TEVA leads in 3 of 6 categories (Valuation Metrics, Profitability & Efficiency). SUPN leads in 1 (Income & Cash Flow). 1 tied.
Best OverallTeva Pharmaceutical Industr… (TEVA)Leads 3 of 6 categories
Loading custom metrics...
TEVA vs SUPN: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is TEVA or SUPN a better buy right now?
For growth investors, Supernus Pharmaceuticals, Inc.
(SUPN) is the stronger pick with 8. 6% revenue growth year-over-year, versus 4. 3% for Teva Pharmaceutical Industries Limited (TEVA). Teva Pharmaceutical Industries Limited (TEVA) offers the better valuation at 30. 0x trailing P/E (14. 5x forward), making it the more compelling value choice. Analysts rate Teva Pharmaceutical Industries Limited (TEVA) a "Buy" — based on 46 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — TEVA or SUPN?
On forward P/E, Teva Pharmaceutical Industries Limited is actually cheaper at 14.
5x.
03Which is the better long-term investment — TEVA or SUPN?
Over the past 5 years, Teva Pharmaceutical Industries Limited (TEVA) delivered a total return of +246.
2%, compared to +78. 0% for Supernus Pharmaceuticals, Inc. (SUPN). Over 10 years, the gap is even starker: SUPN returned +228. 4% versus TEVA's -28. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — TEVA or SUPN?
By beta (market sensitivity over 5 years), Supernus Pharmaceuticals, Inc.
(SUPN) is the lower-risk stock at 0. 78β versus Teva Pharmaceutical Industries Limited's 1. 13β — meaning TEVA is approximately 44% more volatile than SUPN relative to the S&P 500. On balance sheet safety, Supernus Pharmaceuticals, Inc. (SUPN) carries a lower debt/equity ratio of 4% versus 2% for Teva Pharmaceutical Industries Limited — giving it more financial flexibility in a downturn.
05Which is growing faster — TEVA or SUPN?
By revenue growth (latest reported year), Supernus Pharmaceuticals, Inc.
(SUPN) is pulling ahead at 8. 6% versus 4. 3% for Teva Pharmaceutical Industries Limited (TEVA). On earnings-per-share growth, the picture is similar: Teva Pharmaceutical Industries Limited grew EPS 182. 8% year-over-year, compared to -151. 5% for Supernus Pharmaceuticals, Inc.. Over a 3-year CAGR, TEVA leads at 5. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — TEVA or SUPN?
Teva Pharmaceutical Industries Limited (TEVA) is the more profitable company, earning 8.
2% net margin versus -5. 4% for Supernus Pharmaceuticals, Inc. — meaning it keeps 8. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TEVA leads at 12. 5% versus -5. 1% for SUPN. At the gross margin level — before operating expenses — SUPN leads at 89. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is TEVA or SUPN more undervalued right now?
On forward earnings alone, Teva Pharmaceutical Industries Limited (TEVA) trades at 14.
5x forward P/E versus 24. 1x for Supernus Pharmaceuticals, Inc. — 9. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SUPN: 14. 8% to $60. 00.
08Which pays a better dividend — TEVA or SUPN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is TEVA or SUPN better for a retirement portfolio?
For long-horizon retirement investors, Supernus Pharmaceuticals, Inc.
(SUPN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 78), +228. 4% 10Y return). Both have compounded well over 10 years (SUPN: +228. 4%, TEVA: -28. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between TEVA and SUPN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(TEVA: 2.3% · SUPN: 38.6%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.